Lebrikizumab maintains atopic dermatitis remission for months off-therapy

Written by The Life Science Feed Editorial Team · Published 5 August 2026 · Edited by Mara Voss

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin condition that significantly impacts quality of life. While effective treatments exist, the prospect of maintaining remission off-therapy remains a critical unmet need for patients and clinicians alike. This study investigated how long lebrikizumab, an IL-13 inhibitor, could sustain stable deep response after treatment discontinuation in patients with moderate-to-severe AD.1
The findings, published in the Journal of Dermatological Treatment, offer a detailed look at the durability of lebrikizumab's effect, specifically examining the relationship between drug serum levels and sustained remission.1

KEY TAKEAWAYS

- The Pivot: Lebrikizumab demonstrated sustained off-therapy remission for up to 38 weeks in a subset of atopic dermatitis patients.
- The Data: Patients achieving stable EASI 90 at Week 52 maintained this response for a median of 38 weeks after stopping treatment.
- The Action: For patients achieving deep and stable responses, a treatment holiday with lebrikizumab may be a viable option, though careful monitoring is essential.

Atopic dermatitis, a condition affecting millions across Europe, often necessitates long-term systemic therapy to control its debilitating symptoms. The goal of any effective treatment extends beyond acute symptom resolution; it aims for sustained disease control and, ideally, periods of remission where patients can reduce or cease medication. Lebrikizumab, a monoclonal antibody targeting interleukin-13 (IL-13), has shown efficacy in moderate-to-severe AD, but the duration of its effect after treatment cessation has been a key question for clinicians managing chronic disease.1
This particular analysis focused on a specific cohort of patients from a broader clinical program. Investigators included adults and adolescents with moderate-to-severe AD who had initially responded to lebrikizumab monotherapy. The study design specifically targeted patients who achieved a stable Eczema Area and Severity Index (EASI) 90 response post-induction and maintained this deep response up to Week 52 of continuous therapy. This stringent selection criterion aimed to identify those most likely to benefit from a treatment holiday, providing a clearer picture of the drug's true off-therapy potential.1

Defining and Measuring Off-Therapy Remission

The primary objective of the study was to evaluate the relationship between lebrikizumab serum levels and the duration of stable deep response after treatment cessation. Patients who achieved EASI 90 at Week 16 and maintained this response

through Week 52 were eligible for treatment discontinuation. EASI 90, representing a 90% improvement from baseline in the EASI score, signifies a near-complete clearance of skin lesions, a high bar for therapeutic success in AD. The investigators meticulously tracked these patients, monitoring for loss of EASI 90 response and correlating this with residual lebrikizumab levels.1

The study defined stable deep response as maintaining EASI 90 at specific time points. This was not merely a transient improvement but a sustained level of disease control. Patients were followed for up to 38 weeks after their last dose of lebrikizumab, or until they experienced a loss of EASI 90. This approach allowed for a direct assessment of how long the therapeutic effect persisted in the absence of ongoing drug exposure. The median duration of off-therapy remission was the key metric, providing a practical benchmark for clinical planning.1

The Durability of Response

Patients who achieved and maintained stable EASI 90 up to Week 52 demonstrated a median off-therapy remission duration of 38 weeks. This means half of these highly responsive patients maintained their near-clear skin for over eight months after discontinuing lebrikizumab. The range of remission varied, but the median provides a clinically meaningful estimate for patients considering a treatment break. This finding suggests that lebrikizumab's mechanism of action, by blocking IL-13, may induce a more profound and lasting immunological shift in some patients, allowing for extended periods without active treatment.1

The analysis also explored the correlation between residual lebrikizumab serum levels at the time of treatment cessation and the duration of remission. While specific quantitative data on this correlation were not detailed in the abstract, the study design explicitly aimed to evaluate this relationship. This suggests that higher or more sustained drug levels at the point of discontinuation might predict longer off-therapy periods, a hypothesis that warrants further investigation with full data. Understanding this pharmacokinetic-pharmacodynamic link could help personalise treatment cessation strategies.1

The patient population included both adults and adolescents, reflecting the broad impact of AD across age groups. While the abstract does not break down the remission duration by age cohort, the inclusion of adolescents is important. AD often presents in childhood and can persist into adulthood, making long-term management strategies, including potential treatment holidays, particularly relevant for younger patients and their families. The ability to achieve prolonged remission could reduce cumulative drug exposure over a lifetime.1

Where the Data Offers Clarity and Raises Questions

This study provides clear evidence that a subset of patients with moderate-to-severe AD can achieve substantial, durable remission off-therapy with lebrikizumab. The 38-week median duration is a significant period for patients who typically face continuous treatment. It offers a tangible goal for those seeking to minimise medication burden while maintaining disease control. For a clinician, this data provides a basis for discussing treatment holidays with well-controlled patients, a conversation that previously lacked robust evidence for many AD therapies.1

But the study focused exclusively on patients who achieved a stable EASI 90 response by Week 52. This is a highly selected population, representing the best responders to lebrikizumab. It does not provide insight into the off-therapy remission rates or durations for patients who achieve less stringent endpoints, such as EASI 75, or those who do not maintain such a deep response for a full year. The generalisability of these findings to the broader AD population,

including those with less profound initial responses, remains an open question. Clinicians should interpret these results within the context of this specific, high-responder cohort.1

The study's reliance on EASI 90 as the sole measure of stable deep response is appropriate for assessing skin clearance. But AD is a complex disease with multiple facets, including pruritus, sleep disturbance, and quality of life impacts. While EASI 90 often correlates with improvements in these other domains, the study did not explicitly detail the off-therapy trajectory of these patient-reported outcomes. A comprehensive understanding of off-therapy remission would ideally include sustained improvements in itch and quality of life, not just objective skin scores.1

The abstract also does not detail the safety profile during the off-therapy period. While lebrikizumab is generally well-tolerated, understanding any potential rebound flares or adverse events upon cessation is critical for patient management. The full paper would likely elaborate on this, but its absence here means clinicians must proceed with caution, ensuring close monitoring for disease recurrence or new symptoms during any treatment holiday. The potential for a rebound effect, even if mild, needs to be factored into patient counselling.1

The open-label nature of the long-term extension from which these patients were drawn is an obvious caveat. While the assessment of EASI 90 is relatively objective, the overall context of an open-label study can introduce biases. However, for evaluating off-therapy duration, the primary endpoint is clear: loss of EASI 90. This objective measure helps mitigate some of the concerns associated with open-label designs. Still, future studies with blinded off-therapy phases would provide even stronger evidence.1

The study also did not explore factors that might predict which EASI 90 responders are most likely to achieve prolonged off-therapy remission. Are there specific biomarkers, demographic characteristics, or disease phenotypes that correlate with this sustained effect? Identifying such predictors would allow for more precise patient selection for treatment holidays, optimising resource allocation and patient outcomes. This remains an area for future research, building on the foundation laid by this analysis.1

"Sustaining deep remission without continuous therapy is the holy grail for chronic conditions like atopic dermatitis. This data moves us closer to that reality for a select group of patients."John Silverberg, MD, PhD, Northwestern UniversityThe median 38-week remission period is a strong indicator of lebrikizumab's potential for disease modification in certain patients. For those who achieve this level of control, the ability to take a break from systemic therapy can significantly improve their quality of life and reduce the long-term burden of medication. This is particularly relevant for a chronic condition that often requires years of management. The data supports a more flexible treatment paradigm for highly responsive patients. For a comprehensive guide to managing such conditions, the Oxford Handbook of Medical Dermatology offers step-by-step guidance on diagnosing and managing various skin conditions, including atopic dermatitis.

What remains to be seen is how these findings will translate into real-world clinical practice. Implementing treatment holidays requires careful patient selection, robust monitoring protocols, and clear communication about the potential for disease recurrence. The next step will be to integrate these findings into treatment algorithms and to further investigate the optimal timing and criteria for attempting off-therapy periods in a broader patient population.

CLINICAL IMPLICATIONS

> The prospect of off-therapy remission in atopic dermatitis is a significant development for both patients and the prescribing clinician. A median 38-week remission period for highly responsive patients means nearly nine months without needing active systemic treatment. This offers a tangible benefit in reducing medication burden and improving quality of life, moving beyond continuous therapy as the only option.
> For clinicians, this data provides a basis for discussing treatment holidays with patients who achieve and maintain a stable EASI 90 response. It is crucial to remember this applies to a highly selected cohort of excellent responders. Applying this strategy to patients with less profound or stable responses would be premature and unsupported by the current evidence.
> The industry will undoubtedly leverage these findings to position lebrikizumab as a therapy offering not just efficacy, but also the potential for treatment flexibility. This could differentiate it in a crowded market of biologics for AD. However, the onus remains on pharmaceutical companies to provide further data on broader patient populations and to clarify the safety profile during off-therapy periods.
> The unanswered question is whether this off-therapy remission induces a true disease modification or simply represents a prolonged pharmacokinetic effect. Future research needs to identify biomarkers that predict sustained remission and to establish clear guidelines for patient selection and monitoring during treatment holidays. Until then, careful patient selection and close follow-up are paramount.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. 1. Silverberg JI, Bieber T, Eyerich K. Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitis. J Dermatolog Treat 2026. PMID: 41814992.

LICENCE & RIGHTS

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com